SLU7 and myelodysplastic syndrome: PRMTs catalyze the methyl transfer to the arginine residues of protein substrates including splicing factors and it has been proposed that MDS cells carrying splicing factor mutations may have a different sensitivity to PRMTs inhibitors [143].